Boston Scientific (NYSE:BSX) today touted data from a Phase 3 clinical trial of its TheraSphere Y-90 glass microspheres treatment. In the trial, the TheraSphere treatment successfully met both primary endpoints, including progression-free survival (PFS) and hepatic progression-free survival (hPFS) in patients with metastatic colorectal cancer (mCRC) of the liver. Get the full story at our sister […]
Oncology
Ibex appoints new CMO, moves CEO to Boston to lead U.S. expansion
Ibex Medical Analytics announced today that it appointed Dr. Douglas Clark as its new chief medical officer. In addition to appointing Clark to its executive team, Ibex announced that co-founder & CEO Joseph Mossel will relocate to the U.S. to lead its North American expansion efforts from its Boston headquarters. Clark previously served as CMO […]
Novocure wins FDA breakthough designation for liver tumor treatment device
Novocure (NSDQ:NVCR) announced today that the FDA granted breakthrough designation for its NovoTTF-200T liver cancer treatment system. St. Helier, Jersey-based Novocure designed its NovoTTF-200T system, a tumor treating fields (TTFields) delivery system for use in tandem with atezolizumab and bevacizumab for the first-line treatment of patients with unresectable or metastatic liver cancer. According to a […]
Illumina, Merck partner on diagnostics for identifying specific cancer mutations
Illumina (NSDQ:ILMN) and Merck today announced a partnership to develop diagnostics for identifying certain genetic mutations. The partnership aims to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD), leveraging Illumina’s TruSight Oncology 500 (TSO 500) content, enabling what the companies tout as the most comprehensive genomic […]
TriSalus enrolls first patient in pressure-enabled drug delivery trial for treating melanoma
TriSalus Life Sciences announced today that it enrolled the first patient in its clinical study of a treatment for metastatic uveal melanoma. The PERIO-01 clinical study evaluates SD-101, an investigational toll-like receptor 9 (TLR9) agonist in adults with metastatic uveal melanoma through intravascular administration into uveal melanoma liver metastasis lesions in combination with checkpoint inhibitors using […]
Boston Scientific touts future of its MedSurg segment
Boston Scientific executive Dave Pierce sees a bright future for the company’s GI endoscopy and urology technologies. As many companies did, Boston Scientific (NYSE:BSX) had to adapt during the COVID-19 pandemic and, with the lessons learned, it may be better for it. Dave Pierce, the EVP of Boston Scientific’s MedSurg segment, certainly thinks so. “Our […]
EU to investigate Illumina’s decision to close $8B Grail acquisition
The European Commission announced that it opened an investigation to assess Illumina’s (NSDQ:ILMN) recently completed acquisition of Grail. Last week, Illumina completed its long-awaited, highly-scrutinized acquisition of the cancer detection company that spun out from Illumina nearly five years ago. The $8 billion acquisition was initially announced in September 2020. Within the announcement of the […]
Illumina completes $8B Grail acquisition, companies remain separate amid European review
Illumina (NSDQ:ILMN) announced that it completed its long-awaited and much-scrutinized acquisition of cancer detection company Grail. Illumina, however, also said in a news release that it will hold Grail as a separate company as the European Commission conducts an ongoing regulatory review. A decision from the EU regulators is projected after the deal expires, but […]
Accuray beats The Street in Q4
Accuray (NSDQ:ARAY) shares dipped this morning despite fourth-quarter results that beat the consensus forecast. The Sunnyvale, Calif.-based radiation oncology company posted losses of -$11.1 million, or -12¢ per share, on sales of $110.9 million for the three months ended June 30, 2021, for a massive bottom-line slide from losses of $152,000 this time last year […]
Novocure plummets on missed Q2 projections
Novocure (NSDQ:NVCR) shares took a dive today on second-quarter results that came up short of the consensus forecast. NVCR shares were down -11.7% at $160.67 in mid-afternoon trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.9% on the day. Get the full story at our sister […]
GE turns to AI to boost MR for cancer therapy planning
GE Healthcare (NYSE:GE) recently announced that it has collaborated with Spectronic Medical to make AI-based software for more precise cancer treatment planning. Spectronic Medical’s AI-based software can be used with GE Healthcare’s AIR Recon DL technology for MR-only based radiotherapy planning for better soft tissue differentiation than traditional CT. Get the full story on our sister […]
